This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Like so many other organizations, BrainsWay continues to monitor the rapidly evolving impacts of coronavirus (COVID-19) closely.
Without question, our top priority is the health and wellbeing of our loyal and growing customer base, the patients they serve, and our employees and their families.
BrainsWay is doing our part to minimize the spread of coronavirus.
We took action by informing our employees of specific guidelines put out by the CDC (Centers for Disease Control and Prevention).
With this, we are practicing “social distancing,” and minimizing all face-to-face meetings.
Additionally, for the duration of March 2020, BrainsWay will not attend or participate in any external events (trade shows, exhibitions, conferences), and we are suspending any non-essential travel.
During this period, we fully understand the importance of patients continuing to receive their Deep TMS treatment, and thus BrainsWay remains fully operational and committed to serving our customers to the best of our abilities.
Thank you for your understanding during this unprecedented time.
Together, we will get through this period of turbulence, and we will emerge stronger and healthier.